N
NeuroKaire
Biotech & Life Sciences · Kearny, United States · Founded 2017
Genetika+ is developing a tailored medical diagnostic instrument to help doctors cure depression. Genetika+ predicts the best pharmacological treatment for each patient, allowing faster treatment MoreLess
Operator of a medical platform intended to personalize depression treatment for every individual. The company's platform leverages biological, medical, and genetic data and innovative technology to predict the optimal drug treatment, and helps pharma companies differentiate product offerings and de-risk clinical trials by identifying responders and stratifying patients, and transforming care for psychiatric and neurological diseases by combining stem-cell technology, genomics, and artificial intelligence for treatment optimization and effective drug development, enabling patients to get access to fast treatment with few side effects and low dosing. Keywords: Pharmaceuticals and Biotechnology, Depression Drugs, Depression Solutions, Depression Treatment, Mental Illness Therapy, Mental Illness Treatment, Mental Wellness.
Talent graph
NeuroKaire's talent
Source: Dealroom Talent Intelligence.
Investors
7 investors on NeuroKaire's cap table
Sourced from Dealroom's funding and investor records.






Global footprint
Where NeuroKaire has talent and traffic
team presence
Market sentiment
What the market is saying about NeuroKaire
An AI-synthesized read of the highest-engagement posts about NeuroKaire on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See NeuroKaire on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.